Industries we serve

Biologics & Pharma

The environment this practice was built in.

GMP biologics and pharmaceutical manufacturing is where this work was proven - the most heavily inspected manufacturing environment there is, where every qualification decision may eventually be read by an investigator. Our track record comes from these floors: qualification paths rebuilt across multi-site operations, on-time completion sustained at 95 percent, new-hire training cut from six months to six weeks with verification rigor added, not removed.

The work in this sector concentrates on the personnel side of the quality system: deviations that trace to people, corrective actions that cite training, and the effectiveness checks that follow twelve months later. When your program has to hold up to FDA scrutiny, the standard is not "training occurred" - it is demonstrated competence, documented in records an investigator can follow.

Medical Device

Where training effectiveness just became the rule.

FDA's Quality Management System Regulation became effective February 2, 2026, incorporating ISO 13485:2016 - and with it, the expectation that manufacturers evaluate training effectiveness rather than accept attendance records. For device manufacturers, the gap between proof of presence and proof of capability is no longer a philosophical point. It is the standard your next inspection reads against.

Device operations tend to arrive with the same underlying pattern: training tracked as completion in the LMS, qualification by informal shadowing, and records that cannot connect a specific person to a specific demonstrated capability. We restructure those programs around defined standards, verified performance, and records built for the audit room - the same discipline proven in biologics, applied to the device floor.

Human Tissue

AATB-regulated operations, inspected firsthand.

Human tissue operations carry a regulatory environment of their own - AATB standards alongside FDA oversight, with donor-to-recipient traceability expectations that make personnel qualification records part of the chain of custody story. We have worked inside these operations directly, and our inspection record includes AATB inspections specifically: nine-plus regulatory and customer inspections including FDA and AATB, with zero training-related findings.

Tissue establishments are frequently leaner than large biologics sites, which makes the qualification system's efficiency matter as much as its rigor: every hour of unstructured shadowing costs proportionally more, and every single point of qualified-person failure is more exposed. Structured qualification paths and honest coverage visibility do disproportionate work here.

General Manufacturing

The same discipline, wherever competence must be proven.

The problems our numbers solve are not biotech problems. Deviations that trace back to people, new hires who take months to reach the floor, and training outcomes that depend on the trainer show up in every manufacturing operation. Wherever a quality system requires evidence of competence - ISO 9001, OSHA, or your own customers' audits - the same discipline applies: define the standard, qualify against it, and keep the proof.

ISO 9001 makes the requirement explicit in Clause 7.2: retain documented information as evidence of competence. Customer audits increasingly ask the same personnel questions an FDA investigator would. And the operational wins - compressed ramp time, consistent trainer delivery, capability visibility for leadership - pay for themselves regardless of who regulates you.

Our AI implementation and training services span all manufacturing types as a first-class practice, not an afterthought: readiness assessment, workflow automation, AI fluency training, and document intelligence apply to any operations-heavy organization with documents, training, and records to run.